Role of virechana (purgation) in diabetes

Clinical evaluation of virechana karma in the management of diabetes mellitus type II

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Observational

Source

CTRI

Registry ID

CTRI/2018/02/011668

Enrollment

Registered

2018-02-02

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Diabetes mellitus type II

Interventions

Intervention1: Group A: 30 Patients under this group will be administered with 2 sittingsof Virechana Karma. After Virechana, patient is administered with placebo drug. Virechana will be given after a

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients having sign & symptoms of Diabetes Mellitus type II. 2. Fasting blood glucose level > 110 mg/dl 3. P.P blood sugar level > 140 mg/dl 4. HbA1c > 6.0% or above 42 mmol/mol 5. Patients eligible for Virechana Karma.

Exclusion criteria

Exclusion criteria: 1. Patient with D.M Type I. 2. Patients suffering from secondary diabetes. 3. Patients suffering from any severe systemic illness. 4. Hypertensive patient with B.P > 200/100 mm of Hg. 5. Patients suffering from Diabetogenic Renal complications. 6. Other contraindication for Virechanakarma indicated in text.

Design outcomes

Secondary

Measure	Time frame
Exacerbation in sign and symptomsTimepoint: 1 month	—

Primary

Measure	Time frame
To evaluate the efficacy of Virechana Karma in the management of Diabetes Mellitus Type II.Timepoint: 2 months	—

Countries

India

Contacts

Public ContactSwati Tiwari

Rishikul Govt. ayurvedic college

ayursanjay44@gmail.com9411754007

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026